Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
| ▸ | JAK3 | P52333 | 5/20 | 0.33 |
| ▸ | JAK1 | P23458 | 4/20 | 0.33 |
| ▸ | TYK2 | P29597 | 3/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5636192 | 0.85 | CHRM1 (0.44) | CHRM1CHRM2CHRM3SMN1; SMN2 | |
| SCHEMBL911107 | 0.84 | CHRM2 (0.59) | CHRM1CHRM2CHRM3 | |
| SCHEMBL911108 | 0.84 | CHRM2 (0.59) | CHRM1CHRM2CHRM3 | |
| SCHEMBL5636057 | 0.80 | CHRM1 (0.56) | CHRM1CHRM2CHRM3GRM5JAK1 | |
| SCHEMBL6309361 | 0.78 | CHRM1 (0.46) | CHRM1CHRM2CHRM3 | |
| SCHEMBL16421281 | 0.77 | CHRM2 (0.67) | CHRM1CHRM2CHRM3 | |
| SCHEMBL18662292 | 0.77 | CHRM2 (0.67) | CHRM1CHRM2CHRM3 | |
| SCHEMBL20635018 | 0.77 | CHRM2 (0.67) | CHRM1CHRM2CHRM3 | |
| SCHEMBL1029630 | 0.77 | CHRM2 (0.67) | CHRM1CHRM2CHRM3 | |
| SCHEMBL18682177 | 0.77 | CHRM2 (0.67) | CHRM1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054912-A1 | Modulators of acetylcholine receptors | ASTLES PETER C | 2007-03-08 | — | — | US | disclosed |
| US-7148236-B2 | Modulators of acetylcholine receptors | MERCK & CO., INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050182088-A1 | Modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182088-A1 | Modulators of acetylcholine receptors | CHRM3, CHRNG, CHRM5 | CHRM1 22/4885CHRM2 17/4885CHRM3 1/4885 |
| US-20070054912-A1 | Modulators of acetylcholine receptors | CHRM3, CHRNG, CHRM5 | CHRM1 17/4885CHRM2 6/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.